Controlled ovarian hyperstimulation pharmacogenetics a simplified model to genetically disect estrogen-related diseases

Pharmacogenomics

Volumn 8, Issue 7, 2007, Pages 775-785

  Morón, Francisco Jesús ^a   Galán, José Jorge ^a   Ruiz, Agustín ^a  

^a Neocodex SL   (Spain)

Author keywords

BMP15; Diseases; ERD; ESR1; ESR2; Estrogen; FSH; FSHR; Pharmacogenetics

Indexed keywords

BONE MORPHOGENETIC PROTEIN 15; ESTROGEN; ESTROGEN RECEPTOR; FOLLITROPIN;

BREAST CANCER; CLINICAL PROTOCOL; DRUG EFFICACY; ESSENTIAL HYPERTENSION; ESTROGEN ACTIVITY; ESTROGEN SYNTHESIS; GENETIC MARKER; HORMONAL THERAPY; HUMAN; INFERTILITY THERAPY; MODEL; OSTEOPOROSIS; OVARY HYPERSTIMULATION; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC MARKERS; HUMANS; INFERTILITY, FEMALE; MICE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION; PHENOTYPE;

EID: 34548104841     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.7.775     Document Type: Review

References (77)

1. Motsinger AA, Ritchie MD: Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum. Genomics 2, 318-328 (2006).
2. Hoh J, Ott J, Related Genetic dissection of diseases: design and methods. Curr. Opin. Genet. Dev. 14, 229-232 (2004).
3. Dreifus C: An economist examines the business of fertility. New York Times, 28th February 2006.
4. Salha O, Balen AH: New concepts in superovulation strategies for assited conception treatments. Curr. Opin. Obstet. Gynecol. 12, 201-206(2000).
5. Kligman I, Rosenweks Z: Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. Fertil. Steril. 76, 1185-1190 (2001).
6. de Castro F, Moron FJ, Montoro L, Real LM, Ruiz A: Pharmacogenetics of controlled ovarian hyperstimulation. Pharmacogenomics 6, 629-637 (2005).
7. Greb RR, Behre HM, Simoni M: Pharmacogenetics in ovarian stimulation - current concepts and future options. Reprod. Biomed. Online. 11, 589-600 (2005).
8. Nikolaou D, Lavery S, Turner C, Margara R, Trew G: Is there a link between an extremely poor response to ovarian hyperstimulation and early ovarian failure? Hum. Reprod. 17, 1106-1111 (2002).
9. Knight PG, Glister C: TGF-β superfamily members and ovarian follicle development. Reproduction 132, 191-206 (2006).
10. Spearow JL, Nutson PA, Mailliard WS, Porter M, Barkley M: Mapping genes that control hormone-induced ovulation rate in mice, Biol. Reprod. 61, 857-872 (1999).
11. Spearow JL, Barkley M: Genetic control of hormone-induced ovulation rate in mica Biol. Reprod. 61, 851-856 (1999).
12. McNatty KP, Moore LG, Hudson NL et al.: The oocyte and its role in regulating ovulation rate: a new paradigm in reproductive biology. Reproduction 128, 379-386 (2004).
13. Chu MX, Liu ZH, Jiao CL et al.: Mutations in BMPR-IB and BMP-15 genes are associated with litter size in Small Tailed Han sheep (Ovisaries). J. Anim. Sci. 85, 598-603 (2007).
14. Galloway SM, McNatty KP, Cambridge LM et al.: Mutations in an oocyte-derived growth factor gene(BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat. Genet. 25, 279-283, (2000).
15. Hanrahan JP, Gregan SM, Mulsant P et al.: Mutations in the genes for oocyte-derived growth factors GDF9 and BMP15 are associated with both increased ovulation rate and sterility in Cambridge and Belclare sheep (Ovisaries). Biol. Reprod. 70, 900-909 (2004).
16. Bodin L, Di Pasquale E, Fabre S et al.: A novel mutation in the bone morphogenetic protein 15 gene causing defective protein secretion is associated with both increased ovulation rate and sterility in Lacaune sheep. Endocrinology 148, 393-400 (2007).
17. Gemmell NJ, Slate J: Heterozygote advantage for fecundity. PLoS ONE 1, E125 (2006).
18. Mulsant P, Lecerf F, Fabre S et al.: Mutation in bone morphogenetic protein receptor-IB is associated with increased ovulation rate in Booroola Merino ewes. Proc. Natl Acad. Sci. USA 98, 5104-5109 (2001).
19. Wilson T, WU XY, Juengel JL et al.: Highly prolific Booroola sheep have a mutation in the intracellular kinase domain of bone morphogenetic protein IB receptor (ALK-6) that is expessed in both oocytes and granulosa cells Biol. Reprod. 64, 1225-1235 (2001).
20. Davis GH, Balakrishnan L, Ross IK et al.: Investigation of the Booroola (FecB) and Inverdale(FecX[I]) mutations in 21 prolific breeds strains of sheep sampled in 13 countries, Anim. Reprod. Sci. 92, 87-96 (2006).
21. Davis GH, Galloway SM, Ross IK et al.: DNA tests in prolific sheep from eight courtries provide new evidence on origin of the Booroola (FecB) mutation. Biol. Reprod. 66, 1869-1874 (2002).
22. McNatty KP, Hudson N, Smith P, Juengel JL: The effects of superovulating sheep with mutations in either the activin-like kinase (Alk6) or bone morphogenetic protein (BMP15) genes on ovulation rate and embryo production. J Reprod. Dev. 52 S39-S43 (2006).
23. Klinkert ER, te Velde ER, Weima S et al.: FSH receptor genotype is associated with pregnancy but not with ovarian response in IVF. Reprod. Biomed. 13, 687-695 (2006).
24. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M: Ovarian response to follicle-stimulating hormone (FSH) stimulation depands on the FSH receptor genotype, J Clin. Endocrinol. Metab. 85, 3365-3369 (2000).
25. Behre HM, Greb RR, Mempel A et al.: Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet. Genomics 15, 451-456 (2005).
26. Sudo S, Kudo M, Wada S, Sato O, Hsueh AJ, Fujimoto S: Genetic and functional anlyses of polymorphisms in the human FSH receptor gene Mol. Hum Reprod. 8, 893-899 (2002).
27. Falconer H, Anderson E, Aanesen A, Fried G: Follicle-stimulating hormone receptor polymorphisms in a population of infertile women. Acta Obstet. Gynecol. Scand. 84, 806-811 (2005).
28. de Castro F, Ruiz R, Montoro L et al.: Role of follicle stimulating hormone receptor Ser68OAsn polymorphism in the efficacy of follicle-stimulating hormone. Fertil. Steril. 80, 571-576 (2003).
29. de Castro F, Moran FJ, Montoro L et al.: Human controlled ovarian hyperstimulation outcome is a polygenic trait. Pharmacogenetics 14, 285-293 (2004).
30. Loutradis D, Patsoula E, Minas V et al.: Related FSH receptor gene polymorphism. have a role for different overian response to stimulation in patients entering IVF/ICSI-ET program. J. Assist. Reprod. Genet. 23, 177-184 (2006).
31. Jun JK, Yoon JS, Ku SY et al.: Follicle-stimulating hormone receptor gene polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET. J. Hum. Genet. 51, 665-670 (2006).
32. Daelemans C, Smits G, de Maertelaer V et al.: Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormome receptor Sar68OAsn polymorphism. J. Clin. Endocrinol. Metab. 89, 6310-6315 (2004).
33. D'Alva CB, Serafini P, Motta E, Latronico AC, Mendonca BB: Letter re: FSH receptor polymorphism and iatrogenic ovarian hyperstimulation. J. Clin. Endocrinol. Metab. 90, 4978 (2005).
34. Kerkela E, Skottman H, Friden B, Bjuresten K, Kere J, Hovatta O: Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormome receptor genes as the cause of ovarian hyperstimulation syndrome, Fertil. Steril. 87, 603-606 (2007).
35. Simoni M, Gromoll J, Hoppner W et al.: Mutational analysis of the follicle-stimulating hormone (FSH) receptor in normal and infertile men: identification and characterization of two discrete FSH receptor isoforms, J Clin. Endoocrinol. Metab. 84, 751-755 (1999).
36. Ahda Y, Gromoll J, Wunsch A et al.: Follicle-stimulating hormone receptor gene haplotype distribution in normozoospermic and azoospermic men. J Androl. 26, 494-499 (2005).
37. Galan JJ, Buch B, Cruz N et al.: Multilocus anslyses of estrogen-related genes reveal involvement of the ESR1 gene in male infertility and the polygenic nature of the pathology. Fertil. Steril. 84, 910-918 (2005).
38. Pengo M, Ferlin A, Arredi B et al.: FSH receptor genepolymorphismin in fertile and infertile Italian men. Reprod. Biomed. Online 13, 795-800 (2006).
39. Nakayama T, Kuroi N, Sano M et al.: Mutation of the folliclde-stimulating hormone receptor gene 5′-untranslated region associated with female hypertension. Hypertension 48, 512-518 (2006).
40. Sun L, Peng Y, Sharrow AC et al.: FSH directly regulates bone mass Cell 125, 247-260 (2006).
41. Moron FJ Mendoza N, Vazquez F et al.: Multilocus analysis of estrogen-related genes in Spanish postmenopausal women suggests an interactive role of ESR1, ESR2 and NRIP1 genes in the pathogenesis of osteoporosis. Bone 39, 213-221 (2006).
42. Yang CQ, Chan KY, Ngan HY et al.: Single nuceleotide polymorphism of follicle-stimulating hormone receptor are associated with ovaian cancer susceptibility. Carcinogenesis 27, 1502-1506 (2006).
43. Georgiou I, Konstantelli M, Syrrou M, Messenis IE, Lolis DE: Oestrogen receptor gene polymorphism and ovarian stimulation for in vitro fertilization. Hum. Reprod. 12, 1430-1433 (1997).
44. Sundarrajan C, Liao W, Roy AC, Ng SC: Association of oestrogen receptor gene polymorphisms with outcome of ovarian stimulation in patients undergoing IVF, Mol. Hum. Reprod. 5, 797-802,(1999).
45. Becker KG: The common variants/multiple disease hypothesis of common complex genetic disorders. Med. Hypotheses 62, 309-317 (2004).
46. Ioannidis JP, Ralston SH, Bennett ST et al.: Differential genetic effects of ESR1 gene polymorphism on osteoporosis outcomes JAMA 292, 2105-2114 (2004).
47. van Meurs JB, Schuit SC, Weel AE et al.: Association of 5′ estrogen receptor-α gene polymorphism with bone mineral density, vertebral bone area and fracture risk. Hum Mol. Genet. 12, 1745-1754 (2003).
48. Lau HH, Ho AY, Luk KD, Kung AW: Estrogen receptor-β gene polymorphisms are associated with higher bone mineral density in premenopausal, but not postmenopausal southern Chinese women. Bone 31, 276-281 (2002).
49. Ogawa S, Hosoi T, Shiraki M et al.: Association of estrogen receptor-β gene polymorphism with bone mineral density. Biochem. Biophys Res Commun. 269, 537-541 (2000).
50. Cai Q, Shu XO, Jin F et al.: Genetic polymorphism in the estrogen receptor-α gene and risk of breast cancer: Results from the Shanghai Breast Cancer Study. Cancer Epidemiol. Biomarkers Prev. 12, 853-859 (2003).
51. Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH: The estrogen receptor-α gene and breast cancer risk (The Netherlands). Cancer Causes Control 16, 1195-1202 (2005).
52. Kitawaki J, Obayashi H, Ishihara H et al.: Oestrogen receptor-α gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum. Reprod. 16, 51-55 (2001).
53. Brandi ML, Becherini L, Gennari L et al.: Association of the estrogen receptor-α gene polymorphisms with sporadic Alzheimer's disease. Biochem. Biophys Res Commun. 265, 335-338 (1999).
54. Forsell C, Enmark E, Axelman K et al.: Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer's disease. Eur. J. Hum. Genet. 9, 802-804 (2001).
55. Galan JJ, Guarducci E, Nuti F et al.: Molecular analysis of estrogen receptor-α gene AGATA haplotype and SNP12 in European populations potential protective effect for cryptorchidism and lack of association with male infertility. Hum Reprod. 22, 444-449 (2007).
56. Guarducci E, Nuti F, Becherini L et al.: Estrogen reoeptor-α promoter polymorphism: stronger estrogen action is coupled with low sperm count. Hum. Reprod. 21, 994-1001 (2006).
57. Suzuki Y, Sasagawa I, Itoh K, Ashida J, Muroya K, Ogata T: Estrogen receptor-α gene polymorphism is associated with idiopathic azoospermia. Fertil. Steril. 78, 1341-1343 (2002).
58. Kukuvitis A, Georgiou I. Bouba I et al.: Association of oestrogen receptor-α polymorphisms and androgen receptor CAG trinucleotide repeats with male infertility: a study in 109 Greek infertile men. Int. J. Androl. 25, 149-152 (2002).
59. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K: A comprehensive review of genetic association studies. Genet. Med. 4. 45-61 (2002).
60. Rivadeneira F, van Meurs JB, Kant J et al.: Estrogen receptor-β (ESR2) polymorphisms in interaction with estrogen receptor-α (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women. J. Bone Miner. Res 21, 1443-1456 (2006).
61. Gold B, Kalush F, Bergeron J et al.: Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res. 64, 8891-8900 (2004).
62. Stavrou I, Zois C, Chatzikyriakidou A, Georgiou I, Tsatsoulis A: Combined estrogen receptor-α and estrogen receptor-β genotypes influence the age of menarche. Hum. Reprod. 21, 554-557 (2006).
63. Chang H, Brown CW, Matzuk MM: Genetic analysis of the mammalian transforming growth factor-β superfamily Endocr. Rev. 23, 787-823 (2002).
64. di Pasquale E, Beck-Peccoz P, Persani L: Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am. J. Hum. Genet. 75, 106-111 (2004).
65. Moron FJ, de Castro F, Royo JL et al.: Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenet. Genenomics 16, 485-495 (2006).
66. Laissue P, Christin-Maitre S, Touraine P et al.: Mutations and sequence variants in GDF9 and BMP15 in petients with premature ovarian failure. Eur. J. Endocrinol. 154, 739-744 (2006).
67. Dixit H, Rao LK, Padmalatha VV et al.: Missense mutations in the BMP15 gene are associated with ovarian failure. Hum. Genet. 119, 408-415 (2006).
68. di Pasquale E, Rossetti R, Marozzi A et al.: Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J. Clin. Endocrinol. Metab. 91, 1976-1979 (2006).
69. Chand AL, Ponnampalam AP, Harris SE, Winship IM, Shelling AN: Mutational analysis of BMP15 and GDF9 as candidate genes for premature ovarian failure. Fertil. Steril. 86, 1009-1012 (2006).
70. Moron FJ, Mendoza N, Quereda F et al.: Pyrosequencing technology for automated detection of the BMP15 A180T variant in Spanish postmenopausal women. Clin. Chem. 53, 1162-1164 (2007).
71. Dulitzky M, Cohen SB, Inbal A et al.: Increased prevalence of thrombophilia among woman with severe ovarian hyperstimulation syndrome. Fertil. Steril. 77, 463-467 (2002).
72. McGowan BM, Kay LA, Perry DJ: Deep vein thrombosis followed by internal jugular vein thrombosis as a complication of in vitro fertilization in a woman heterozygous for the prothrombin 3′ UTR and factor V Leiden mutations. Am. J. Hematol. 73, 276-278 (2003).
73. Fabregues F, Tassies D, Raverter JC, Carmona F, Ordinas A, Balasch J: Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening. Fertil. Steril. 81, 989-995 (2004).
74. Machac S, Lubusky M, Prochazka M, Streda R: Prevalence of inherited thrombophilia in patients with severe ovarian hyperstimulation syndrome. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech Repub. 150, 289-292 (2006).
75. Thaler CJ, Budiman H, Ruebsamen H, Nagel D, Lohse P: Effects of the common 677C>T mutation of the 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene on overian responsiveness to recombinant follicle-stimulating hormone. Am. J. Reprod. Immunol. 55, 251-258 (2006).
76. Wunsch A, Ahda Y, Banaz-Yasar F et al.: Single-nucleotide polymorphisms in the promoter region influence the expression of the human follicle-stimulating hormone receptor. Fertil. Steril. 84, 446-53 (2005).
77. Loutradis D, Patsoula E, Stefanidis K et al.: Follicle-stimulating hormone receptor gene mutations are not evident in Greek women with premature ovarian failure and poor responders. Gynecol. Obstet. Invest. 61, 56-60 (2006).